127 related articles for article (PubMed ID: 18429587)
1. What's in the pipeline.
Glazer WM
Behav Healthc; 2007 Dec; 27(12):19-21. PubMed ID: 18429587
[No Abstract] [Full Text] [Related]
2. Psychopharmacology update: why choose quetiapine for bipolar illness?
Tobin ML
Issues Ment Health Nurs; 2007 Apr; 28(4):437-9. PubMed ID: 17454294
[No Abstract] [Full Text] [Related]
3. The approval of mifepristone (RU486) in the United States: What's wrong with this picture?
Blumenthal P; Johnson J; Stewart F
Medscape Womens Health; 2000; 5(4):E7. PubMed ID: 11109052
[No Abstract] [Full Text] [Related]
4. Indications.
Oldham J
J Psychiatr Pract; 2008 May; 14(3):133. PubMed ID: 18520781
[No Abstract] [Full Text] [Related]
5. The use of antipsychotic agents in the management of behavioral disorders in the elderly with dementia: evaluating recent clinical data.
Worz CR
Director; 2008; 16(2):17-20. PubMed ID: 19343879
[No Abstract] [Full Text] [Related]
6. Drug pipeline: Q310.
Peng W
Nat Biotechnol; 2010 Oct; 28(10):998. PubMed ID: 20944578
[No Abstract] [Full Text] [Related]
7. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ
Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875
[No Abstract] [Full Text] [Related]
8. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
9. More treatment options emerge.
Glazer WM
Behav Healthc; 2009 Jun; 29(6):20-1. PubMed ID: 19655578
[No Abstract] [Full Text] [Related]
10. Clozaril approved for reducing risk of suicide.
FDA Consum; 2003; 37(2):5. PubMed ID: 12715754
[No Abstract] [Full Text] [Related]
11. Drug pipeline: Q311.
Peng W
Nat Biotechnol; 2011 Oct; 29(10):859. PubMed ID: 21997619
[No Abstract] [Full Text] [Related]
12. What's new in clinical pharmacology and therapeutics.
Chawla PS; Kochar MS
WMJ; 2004; 103(1):13-9. PubMed ID: 15101461
[TBL] [Abstract][Full Text] [Related]
13. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
[No Abstract] [Full Text] [Related]
14. Neuroleptics: increased mortality in elderly patients.
Prescrire Int; 2005 Dec; 14(80):225. PubMed ID: 16402446
[No Abstract] [Full Text] [Related]
15. Errors in 'Trials and error'.
Miller DD
Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048
[No Abstract] [Full Text] [Related]
16. Drug development research: the process.
Sataloff RT
Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
[No Abstract] [Full Text] [Related]
17. Drug pipeline: Q312.
DeFrancesco L
Nat Biotechnol; 2012 Dec; 30(12):1164. PubMed ID: 23222776
[No Abstract] [Full Text] [Related]
18. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
19. The ODAC chronicles: part 1. My first ODAC experience.
Grillo-López AJ
Expert Rev Anticancer Ther; 2004 Oct; 4(5):709-12. PubMed ID: 15485306
[No Abstract] [Full Text] [Related]
20. Drug development: improving the process.
Peck CC
Food Drug Law J; 1997; 52(2):163-7. PubMed ID: 10557553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
